Overview

Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

Status:
Suspended

Trial end date:
2004-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca